Gland Pharma shares: Promoter Fosun Pharma likely to divest 5% equity worth Rs 2,279 crore via block deal

Fosun Pharma is likely to divest 5% equity in Gland Pharma via a block deal, according to reports. Fosun Pharma Industrial, the promoter of the company, holds 8,53,93,894 shares or 51.77% stake in the pharmaceutical company as of the quarter ended June 30, 2026, as per BSE data.

According to reports, a block deal has been launched in Gland Pharma through which Fosun Pharma will offload its stake. The floor price for the block deal is set at Rs 2,763 per share, which is at a discount of up to 5% to the current market price.

The offer size is pegged at Rs 2,279.5 crore. There will be a lock-up on further sale of shares up to 12 months.


On the market front, Gland Pharma shares settled at Rs 2,904.85 apiece on Thursday, up 1.39% from the previous close of Rs 2,865.15, according to BSE data. The pharma counter traded in the range of Rs 2,929.90 to Rs 2,850.00 during the day. For the year-till-date the pharma counter has appreciated by 69.96%.

The company has a market capitalisation of Rs 47,920.34 crore on the BSE, as of September 3, 2026.

ALSO READ: Up to 290% gains! SBI, Federal Bank make massive windfall as Arcil’s Rs 733-crore IPO hits D-Street

Earlier on September 1, 2026, the company had informed the exchanges that the United States Food and Drug Administration (USFDA) had conducted a routine Good Manufacturing Practice (GMP) Inspection at the Company’s VSEZ Sterile Oncology Formulations Facility and API Facility at Visakhapatnam between August 24, 2026 and September 01, 2026. The said inspection was concluded with ZERO (0) Form 483 Observations.

Last month on August 10, Gland Pharma reported a consolidated net profit of Rs 317 crore for Q1FY27, up 47% year-on-year from Rs 216 crore in the corresponding quarter last year. Revenue from operations rose 20% year-on-year to Rs 1,800 crore, compared with Rs 1,506 crore in Q1FY26.During Q1FY27, Gland Pharma’s quarterly R&D investment stood at Rs 77.2 crore, while adjusted EBITDA increased 37% year-on-year. The adjusted EBITDA margin stood at 28%.The company’s CDMO business contributed 50% of total revenue and recorded 20% year-on-year growth during the quarter. The B2B business accounted for the remaining 50% of revenue and grew 19% year-on-year.

Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer [HK1] of small volume liquid parenteral products, to become one of the largest and fastest growing generic injectables manufacturing companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. The company operates primarily under a business to business (B2B) model and have an excellent track record in the pharmaceutical research and development, manufacturing and marketing of complex injectables.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)